Paratek Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, opened its new corporate headquarters in Boston at 75 Park Plaza. “This move comes at an important time for Paratek, as we have recently initiated a global Phase 3 program for our lead antibiotic compound, omadacycline. With two important products in Phase 3 clinical studies, we are now preparing for the next phase of our g...